MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

MDS Virtual Congress 2020

September 12-16, 2020. Virtual Congress. www.mdscongress.org

View by Title View Categories
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z
  • SYNGAP1-related intellectual disability with ataxia and late onset of epileptic seizures

    N. Gogatishvili, T. Tkemaladze, V. Skrahina, S. Kasradze, A. Rolfs (Tbilisi, Georgia)

  • Tardive Dystonia Successfully treated with DBS

    M. Ferreira Cordellini, D. Benzecry Almeida (Curitiba, Brazil)

  • Targeting the Receptor of Glial Cell Line-Derived Neurotrophic factor to treat Parkinson’s Disease

    Y. Sidorova, A. Mahato, M. Saarma (Helsinki, Finland)

  • Task based profiles of language impairment in Parkinson’s Disease

    A. Lowit, M. Roheger, E. Kalbe, T. Thies, J. Steffen, M. Barbe (Glasgow, United Kingdom)

  • Tau Neuropathology Associates with In Vivo Patterns of Neurodegeneration in Lewy Body Disorders

    N. Spotorno, D. Coughlin, L. Shaw, A. Chen-Plotkin, D. Weintraub, E. Lee, J. Trojanowski, C. McMillan, D. Irwin, M. Grossman (Philadelphia, PA, USA)

  • TAU pathology contributes to specific patterns of structural brain damage and neuropsychological heterogeneity in Huntington’s disease

    S. Martinez-Horta, J. Perez-Perez, R. Perez-Gonzalez, A. Horta-Barba, F. Sampedro, E. Rivas-Asensio, T. Xucla, M. Guasch, A. Campolongo, C. Izquierdo-Barrionuevo, J. Pagonabarraga, J. Kulisevsky (Barcelona, Spain)

  • Technology-based therapy response and prognostic biomarkers in Parkinson’s disease: results from a prospective evaluation of a de novo PD patients’ cohort

    G. Di Lazzaro, M. Ricci, T. Schirinzi, S. Scalise, G. Saggio, N.B Mercuri, A. Pisani (Rome, Italy)

  • Temporal characterization of motor, gastrointestinal, and behavioral symptoms in a SNCA A53T transgenic mouse model of Parkinson’s disease

    N. Radisavljevic, M. Cirstea, K. Bauer, B. Finlay (Vancouver, BC, Canada)

  • Temporal properties of resting-state functional MRI are associated with ON/OFF levodopa MDS-UPDRS III scores in patients with Parkinson’s disease

    M. Morrison, A. Lee, S. Wang, A. Martin, I. Bledsoe, J. Ostrem, P. Larson, P. Starr, D. Wang (San Francisco, CA, USA)

  • Temporhythmal Correction: The New Way of Therapy and Diagnostic Secondary Vascular Parkinsonism

    D.T Akramova (Tashkent, Uzbekistan)

  • « Previous Page
  • 1
  • …
  • 127
  • 128
  • 129
  • 130
  • 131
  • …
  • 149
  • Next Page »
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • #25062 (not found)
    • Welcome to the MDS Abstracts Site
    • Effect of marijuana on Essential Tremor: A case report
    • Advanced Search
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley